Decoy Therapeutics Inc. (DCOY) Income Statement
DCOY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDCOY revenue and net income
DCOY profit margins
DCOY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DCOY quarterly EPS vs estimates
Decoy Therapeutics beat the analyst EPS estimate in 5 of the last 7 quarters. Next report: November 13, 2026.
DCOY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.8M | $5.2M | $3.5M | $838,142 | $1.3M | $1.0M |
| Cost of revenue | $8.5M | $4,424 | $10,051 | $6,677 | $19,183 | $0 | $0 | $430,750 | $506,530 | $662,747 |
| Gross profit | −$8.5M | −$4,424 | −$10,051 | −$6,677 | $1.8M | $5.2M | $3.5M | $407,392 | $767,969 | $347,916 |
| Research & development | $368,170 | $770,027 | $7.2M | $15.8M | $8.5M | $6.9M | $4.0M | $11.9M | $17.0M | $20.4M |
| Sales, general & admin | $3.7M | $5.0M | $5.7M | $7.1M | $6.1M | $6.1M | $7.7M | — | — | — |
| Total operating expenses | $4.1M | $5.7M | $12.9M | $31.8M | $12.8M | $13.0M | $11.7M | $22.5M | $35.5M | $40.2M |
| Operating income | −$12.6M | −$5.7M | −$12.9M | −$31.8M | −$12.8M | −$7.8M | −$8.3M | −$22.1M | −$34.7M | −$39.9M |
| Interest income | $95,472 | $158,539 | $352,251 | $218,730 | — | — | — | — | — | — |
| Interest expense | — | — | — | — | — | $3,047 | — | — | — | — |
| Income before taxes | −$12.5M | −$5.6M | −$12.5M | −$31.6M | −$12.8M | −$7.4M | −$6.9M | −$21.9M | −$34.4M | −$39.5M |
| Net income | −$12.5M | −$5.6M | −$12.5M | −$31.6M | −$12.8M | −$7.4M | −$6.9M | −$21.9M | −$34.4M | −$39.5M |
| EBITDA | −$12.5M | −$5.6M | −$12.5M | −$23.0M | −$12.7M | −$7.6M | −$8.1M | −$21.8M | −$34.4M | −$39.6M |
| EPS (diluted) | $19.90 | −$4141.01 | −$6528.81 | −$15542.51 | −$7560.09 | −$17604.10 | −$5.88 | −$413617.90 | −$1796252.51 | −$2192834.04 |
| Gross margin | — | — | — | — | 99.0% | 100.0% | 100.0% | 48.6% | 60.3% | 34.4% |
| Operating margin | — | — | — | — | −696.3% | −148.8% | −238.5% | −2,633.7% | −2,724.6% | −3,946.5% |
| Net margin | — | — | — | — | −693.8% | −140.5% | −200.2% | −2,615.6% | −2,701.7% | −3,907.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $8.5M | $1,106 | $1,106 | $1,106 | $1,106 | $1,105 | $1,106 | $1,107 | $1,105 | $5,608 |
| Gross profit | — | — | −$8.5M | −$1,106 | −$1,106 | −$1,106 | −$1,106 | −$1,105 | −$1,106 | −$1,107 | −$1,105 | −$5,608 |
| Research & development | $1.3M | $749,813 | $114,429 | $61,826 | $116,383 | $75,532 | $175,344 | $137,234 | $214,447 | $243,000 | $59,953 | $1.0M |
| Sales, general & admin | $1.3M | $1.5M | $403,273 | $833,304 | $849,182 | $1.6M | $1.3M | $869,237 | $1.3M | $1.5M | $910,748 | $1.5M |
| Total operating expenses | $2.6M | $2.3M | $517,702 | $895,130 | $965,565 | $1.7M | $1.5M | $1.0M | $1.5M | $1.8M | $970,701 | $2.5M |
| Operating income | −$2.6M | −$2.3M | −$9.0M | −$895,130 | −$965,565 | −$1.7M | −$1.5M | −$1.0M | −$1.5M | −$1.8M | −$970,701 | −$2.5M |
| Interest income | — | $59,111 | $56,907 | $21,663 | — | $9,162 | $24,780 | $34,350 | — | — | — | — |
| Income before taxes | −$2.4M | −$2.2M | −$9.0M | −$873,467 | −$957,825 | −$1.7M | −$1.5M | −$972,121 | −$1.4M | −$1.7M | −$881,796 | −$2.4M |
| Net income | −$2.4M | −$2.2M | −$9.0M | −$873,467 | −$957,825 | −$1.7M | −$1.5M | −$972,121 | −$1.4M | −$1.7M | −$881,796 | −$2.4M |
| EBITDA | −$2.4M | −$2.2M | −$9.0M | −$872,361 | −$956,719 | −$1.7M | −$1.5M | −$971,016 | −$1.4M | −$1.7M | −$880,691 | −$2.4M |
| EPS (diluted) | −$4.46 | −$4.18 | $43.10 | −$21.72 | −$0.45 | −$1.03 | −$1.01 | −$136.80 | −$3412.80 | −$590.40 | −$322.41 | −$936.00 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DCOY's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DCOY financial results
Decoy Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $12.5 million. Diluted earnings per share came to $19.90.
See the DCOY stock overview for the latest quote and news, or the DCOY chart for price history and technical indicators.
DCOY income statement FAQ
Does Decoy Therapeutics have revenue?
Decoy Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Decoy Therapeutics profitable?
No. Decoy Therapeutics reported a net loss of $12.5 million in fiscal 2025.
How much does Decoy Therapeutics spend on research and development?
Decoy Therapeutics spent $0.4 million on research and development in fiscal 2025.
What are Decoy Therapeutics's earnings per share?
Decoy Therapeutics earned $19.90 per diluted share in fiscal 2025, compared with $-4141.01 a year earlier.
When will Decoy Therapeutics report its next earnings?
Decoy Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Decoy Therapeutics's fiscal year end?
Decoy Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.